1 – 10 of 14
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms
(
- Contribution to journal › Article
- 2023
-
Mark
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
(
- Contribution to journal › Article
- 2022
-
Mark
Transcriptomic signatures of tumors undergoing T cell attack
(
- Contribution to journal › Article
- 2021
-
Mark
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
(
- Contribution to journal › Article
-
Mark
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
(
- Contribution to journal › Article
-
Mark
PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung
(
- Contribution to journal › Article
- 2020
-
Mark
Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer
(
- Contribution to journal › Article
- 2019
-
Mark
Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics
(
- Contribution to journal › Article
- 2018
-
Mark
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
(
- Contribution to journal › Article
- 2017
-
Mark
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
(
- Contribution to journal › Article